CompletedPhase 2NCT01267253
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
Studying Adenocarcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- John K ChanNRG Oncology
- Intervention
- Brivanib Alaninate(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2011 – 2014
Study locations (30)
- Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
- UCSF Medical Center-Mount Zion, San Francisco, California, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- The Hospital of Central Connecticut, New Britain, Connecticut, United States
- Beebe Medical Center, Lewes, Delaware, United States
- Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
- Florida Hospital Orlando, Orlando, Florida, United States
- Sarasota Memorial Hospital, Sarasota, Florida, United States
- Memorial Health University Medical Center, Savannah, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Sudarshan K Sharma MD Limited-Gynecologic Oncology, Hinsdale, Illinois, United States
- Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States
- Greater Baltimore Medical Center, Baltimore, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01267253 on ClinicalTrials.govOther trials for Adenocarcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07276360Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in UgandaUganda Cancer Institute
- RECRUITINGPHASE1NCT07454642AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsAvacta Life Sciences Ltd
- RECRUITINGPHASE3NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerNational Cancer Institute (NCI)
- RECRUITINGNCT07359586Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaZhejiang University
- RECRUITINGPHASE1NCT07020117A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsAktis Oncology, Inc.
- RECRUITINGPHASE2NCT06654011IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07153952RT for Adenocarcinoma/Adenosquamous CarcinomaPeking Union Medical College Hospital
- RECRUITINGNCT06733740Ultrasound-guided Thermal Ablation for Papillary Thyroid CarcinomaChinese PLA General Hospital